論文業績

2025年

原著論文

1. Saito H, Jindai K, Shibata T, Sonoda M, Iiyama T. How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan:Findings from a narrative review and stakeholder meetings. Glob Health Med. 2025 Apr 30;7(2):96-105. [Pubmed]
2. Kitadai R, Okuma Y, Shibata T, Kohno T, Koyama T. Corrigendum to "Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository" [Eur J Cancer 220 (2025) 115380]. Eur J Cancer. 2025 Apr 26;222:115439. [Pubmed]
3. Shiga K, Shibata T, Miyata T. Evaluation of drug lag and drug loss in Japan:participation in global phase III oncology trials. Int J Clin Oncol. 2025 Apr 11. [Pubmed]
4. Kitadai R, Okuma Y, Shibata T, Kohno T, Koyama T. Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository. Eur J Cancer. 2025 May 2;220:115380. [Pubmed]
5. Hamada T, Seki M, Nango E, Shibata T, Imai S, Miyata T. Enhancing effects of exercise and neurofeedback: A systematic review and meta-analysis of computer game-based interventions for pediatric ADHD. Psychiatry Res. 2025 Jun;348:116447. [Pubmed]
6. Toyoshima N, Mizuguchi Y, Takamaru H, Nakamura K, Kakugawa Y, Sakamoto T, Shiroyama M, Kawagoe R, Tsuchiya K, Shinmura K, Ikematsu H, Inaba A, Minakata N, Hotta K, Imai K, Takada K, Ito S, Misawa M, Wakamura K, Kudo SE, Tamai N, Sumiyama K, Ito M, Uraoka T, Tomaru S, Matsuda T, Fujimoto A, Shibata T, Saito Y. The Efficacy of Texture and Color Enhancement Imaging Observation in the Detection of Colorectal Lesions: A Multicenter, Randomized Controlled Trial (deTXIon Study). Gastroenterology. 2025 Mar 18:S0016-5085(25)00524-4. [Pubmed]
7. Sekiguchi M, Shinmura K, Sumiyama K, Matsuda T, Han KS, Kim HS, Chiu HM, Chang CY, Lee WJJ, Khor CJL, Lau LH, Pattarajierapan S, Khomvilai S, Miyata A, Shibata T, Saito Y. Protocol for a multicenter randomized controlled trial to assess the usefulness of computer-aided detection systems for colonoscopy in colorectal cancer screening in the Asia-Pacific region (project CAD/NCCH2217). Jpn J Clin Oncol. 2025 Mar 9:hyaf043. [Pubmed]
8. Ando Y, Yanagisawa S, Ohno M, Kurihara H, Ito K, Ichimura M, Anjo K, Inaba M, Nagasaka Y, Sadachi R, Shibata T, Okita N, Nakamura K, Matsumoto H, Yoshii Y, Narita Y. Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. Jpn J Clin Oncol. 2025 Apr 26;55(5):543-546. [Pubmed]
9. Jindai K, Saito H, Morino E, Hase R, Yamato M, Sonoda M, Shibata T, Iiyama T. Hospital Preparedness for Conducting Clinical Research During a Pandemic: A Nationwide Survey Among Designated Medical Institutions for Infectious Diseases in Japan. Health Secur. 2025 Mar-Apr;23(2):82-93. [Pubmed]
10. Shimizu Y, Tsuji K, Narisawa T, Kuchiba A, Shimazu T, Ochi E, Sakurai N, Iwata H, Arai H, Matsuoka Y. Physical activity and exercise behaviour of breast cancer survivors: nationwide cross-sectional survey. BMJ Support Palliat Care. 2025 Apr 2:spcare-2024-005253. [Pubmed]
11. Kitadai R, Yazaki S, Kuchiba A, Yamanaka T, Shiino S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Yoshida T, Hamamoto R, Shimizu C, Shimomura A, Kojima Y, Shimoi T, Momozawa Y, Sudo K, Yoshida M, Sunami K, Hori M, Katanoda K, Shimada Y, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Omata M, Ohtake T, Suto A, Onishi T, Naito Y, Yamashita T, Yonemori K, Kohno T, Shiraishi K. Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer. Cancer Sci. 2025 Apr;116(4):1048-1058. [Pubmed]

 

2024年

原著論文

1. Nishikawa T, Kakunaga S, Tamura K, Ando M, Ozaki T, Kawai A, Ueda T, Kawasaki M, Tomatsuri S, Okamura N, Kamikura M, Hamada A, Yoshida A, Hirakawa A, Shibata T, Nakamura K, Yonemori K. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer. 2024 Nov 15;130(22):3836-3844. [Pubmed]
2. Saito Y, Toyoshima N, Mizuguchi Y, Sakamoto T, Uraoka T, Ikematsu H, Tamai N, Matsuda T, Misawa M, Hotta K, Shibata T. Protocol for a prospective multicenter randomized controlled trial to evaluate the efficacy of texture and color enhancement imaging (TXI) observation in the detection of colorectal lesions (deTXIon study). Jpn J Clin Oncol. 2024 Sep 4;54(9):1052-1056. [Pubmed]
3. Nakamura K, Takeda K, Saito AM, Kato M, Sato S, Nakagawa S, Kawamoto Y, Oki E, Okamoto I, Okamoto H, Katayama H, Mizusawa J, Kaba H, Shibata T, Fukuda H. Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups. Jpn J Clin Oncol. 2024 Jul 7;54(7):748-752. [Pubmed]
4. Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Dabrafenib and trametinib administration in patients with BRAFV600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. EClinicalMedicine. 2024 Feb 2;69:102447. [Pubmed]
5. Ishimaru S, Shimoi T, Sunami K, Nakajima M, Ando Y, Okita N, Nakamura K, Shibata T, Fujiwara Y, Yamamoto N. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial. Int J Clin Oncol. 2024 Feb;29(2):89-95. [Pubmed]
6. Ando Y, Shimoi T, Sunami K, Okita N, Nakamura K, Shibata T, Fujiwara Y, Yamamoto N. Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial. Cancer Sci. 2024 Feb;115(2):555-563. [Pubmed]
7. Truong HT, Nakahara S, Nguyen SH, Le CN, Shinichi T, Kuchiba A, Mai TD, Nguyen HT. Factors Associated With Delayed Hospital Arrival After Stroke Onset: An Observational Study in Thanh Hoa Province, Vietnam. Cureus. 2024 Nov 9;16(11):e73361. [Pubmed]
8. Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung CF, Lu YS, Chang DY, Sohn J, Kim GM, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Sudo K, Kojima Y, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ Breast Cancer. 2024 Aug 22;10(1):76. [Pubmed]
9. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2024 Sep 20;42(27):3207-3217. [Pubmed]
10. Uneno Y, Mori M, Saito J, Otsuki A, Kuchiba A, Sakurai N, Nakaya N, Fujimori M, Shimazu T; INFORM Study 2023 Group. Awareness, information sources, and beliefs regarding palliative care in the general population in Japan: a nationwide cross-sectional survey (INFORM study 2023). Jpn J Clin Oncol. 2024 Nov 2;54(11):1171-1179. [Pubmed]
11. Nishihara K, Nakano S, Yamaji T, Goto A, Hidaka A, Shimazu T, Kuchiba A, Saito M, Kunishima F, Nakaza R, Kato I, Sawada N, Inoue M, Tsugane S, Iwasaki M; Japan Public Health Center‐based Prospective Study Group. Height, body mass index, physical activity, and risk of colorectal cancer in relation to expression of insulin receptor: The Japan Public Health Center-based Prospective Study. Int J Cancer. 2024 Nov 15;155(10):1751-1761. [Pubmed]
12. Nakano S, Yamaji T, Hidaka A, Shimazu T, Shiraishi K, Kuchiba A, Saito M, Kunishima F, Nakaza R, Kohno T, Sawada N, Inoue M, Tsugane S, Iwasaki M. Dietary vitamin D intake and risk of colorectal cancer according to vitamin D receptor expression in tumors and their surrounding stroma. J Gastroenterol. 2024 Sep;59(9):825-835. [Pubmed]
13. Taguri M, Kuchiba A, Yamaji T, Sawada N, Goto A, Iwasaki M, Tsugane S. Importance of Circulating Leptin and Adiponectin in the Causal Pathways Between Obesity and the Development of Colorectal Cancer in Japanese Men. J Epidemiol. 2024 Dec 5;34(12):563-569. [Pubmed]
14. Okamura M, Fujimori M, Otsuki A, Saito J, Yaguchi-Saito A, Kuchiba A, Uchitomi Y, Shimazu T. Patients' perceptions of patient-centered communication with healthcare providers and associated factors in Japan - The INFORM Study 2020. Patient Educ Couns. 2024 May;122時10分8170 [Pubmed].
15. Momosaka T, Saito J, Otsuki A, Yaguchi-Saito A, Fujimori M, Kuchiba A, Katanoda K, Takaku R, Shimazu T. Associations of individual characteristics and socioeconomic status with heated tobacco product harmfulness perceptions in Japan: A nationwide cross-sectional study (INFORM Study 2020) Journal of Epidemiology. 2024: in press [Pubmed].
16. Miyawaki R, Oka K, Otsuki A, Saito J, Yaguchi-Saito A, Kuchiba A, Fujimori M, Kreps GL, Shimazu T, for the INFORM Study Group. Trust in mass media as sources of cancer information: Findings from a nationally representative cross-sectional survey in Japan. Journal of Health Communication. 2024; 29(2):143-154 [Pubmed].
17. Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S and  Tanaka Y. Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: A propensity score analysis of the real-world nationwide database. Annals of the Rheumatic Diseases. 2024; 83(1):103-111 [Pubmed].

2023年

原著論文

1. Ando Y, Shimoi T, Sunami K, Okita N, Nakamura K, Shibata T, Fujiwara Y, Yamamoto N, Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial, Cancer Sci, 2023 Dec 1. doi: 10.1111/cas.16034. [Pubmed]
2. Terada M, Shimazu T, Saito J, Odawara M, Otsuki A, Yaguchi-Saito A, Miyawaki R, Kuchiba A, Ishikawa H, Fujimori M, Kreps GL, for the INFORM Study Group. Age, gender and socioeconomic disparities in Human Papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: A nationally representative cross-sectional survey. Vaccine. 2023; 41(48):7147-7158 [Pubmed].
3. Takahashi K, Yamamoto K, Kuchiba A, Shintani A, Koyama T. Hypothesis testing procedure for binary and multi-class F1-scores in the paired design. Statistics in Medicine. 2023;42(23):4177-4192 [Pubmed].
4. Nakano S, Yamaji T, Shiraishi K, Hidaka A, Shimazu T, Kuchiba A, Saito M, Kunishima F, Nakaza R, Kohno T, Sawada N, Inoue M, Tsugane S, and Iwasaki M, for the Japan Public Health Center-based Prospective Study Group. Smoking and risk of colorectal cancer according to KRAS and BRAF mutation statuses in a Japanese prospective study. Carcinogenesis．2023 ;44(6):476-484 [Pubmed].
5. Saito J, Odawara M, Fujimori M, Kuchiba A, Oyamada S, Saito E, Fukai K, Tatemichi M, Nakamura M, Uchitomi Y, Shimazu T. Interactive assistance via eHealth for small and medium-sized enterprise employers and healthcare manager teams on tobacco control (eSMART-TC): Protocol for a cluster randomized hybrid type II trial  (N-EQUITY2101/J-SUPPORT2102). Implementation Science Communications. 2023;4(1):61 [Pubmed].
6. Mieno MN, Yamasaki M, Kuchiba A, Yamaji T, Ide K, Tanaka N, Sawada N, Inoue M, Tsugane S, Sawabe M, Iwasaki M. Lack of significant associations between single nucleotide polymorphisms in LPAL2-LPA genetic region and all cancer incidence and mortality in Japanese population: the Japan Public Health Center-based Prospective Study. Cancer Epidemiology．2023 85:102395 [Pubmed].
7. Ishikawa H, Ogawa R, Otsuki A, Saito J, Yaguchi-Saito A, Kuchiba A, Fujimori M, Fukuda Y, Shimazu T, for the INFORM Study Group. Effect modification by geographic area on the association between health literacy and self-rated health: A nationwide cross-sectional study in Japan. BMC Public Health. 2023 ;23(1):952 [Pubmed].
8. Shida, D, Kuchiba A, Shibata T, Hamaguchi T, Yamasaki S, Ito M, Kobatake T, Tonooka T, Masaki T, Shiozawa M, Takii Y, Uetake H, Okamura S, Ojima H, Kazama S, Takeyama H, Kanato K, Shimada Y, Murakami Y, Kanemitsu Y. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910. Cancer Science. 2023;114(8):3352-3363 [Pubmed].
9. Machida R, Sakamaki K, Kuchiba A. Clinical Trial Design and Analysis for Comparing Three Treatments with Intra-Individual Right- and Left-Hand Data. Clinical Trials. 2023 [Pubmed]

 

2022年

原著論文

1. Machida R, Sakamaki K, Kuchiba A. Clinical Trial Design and Analysis for Comparing Three Treatments with Intra-Individual Right- and Left-Hand Data. Clinical Trials. 2023 [Pubmed]
2. Araki Y, Yamamoto N, Tanzawa Y, Higashi T, Kuchiba A, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Endo M, Kobayashi E, Tsuchiya H, Kawai A. Family cancer history and smoking habit associated with sarcoma in a Japanese population study. Scientific Reports. 2022: 12(1):17129 [Pubmed] 
3. Yamada M, Shino R, Kondo H, Yamada S, Takamaru H, Sakamoto T, Bhandari P, Imaoka H, Kuchiba A, Shibata T, Saito Y, Hamamoto R. Robust automated prediction of the revised Vienna Classification in colonoscopy using deep learning: development and initial external validation. J Cancer Res Clin Oncol. 2022 Jul 28. [Pubmed]
4. Higashiyama RI, Horinouchi H, Kuchiba A, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. J Cancer Res Clin Oncol. 2022. [Pubmed]
5. Nakamura K, Ozawa H, Shibata T, Ushirozawa N, Hata T, Okita N, Fuse N, Sato N, Ikeda K, Hanaoka H, Maruyama T, Wada M, Shimizu S, Kasai H, Yamamoto Y, Sakurai J, Todaka K, Tashiro S, Yamamoto H. Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation. Ther Innov Regul Sci. 2022 56(2):220-229. [PubMed]
6. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022 18(19):2351-2360. [PubMed]
7. Takahashi K, Yamamoto K, Kuchiba A, Koyama T. Confidence interval for micro-averaged F₁ and macro-averaged F₁ scores. Appl Intell. 2022 52: 4961–4972. [PubMed]
8. Kikuchi K, Yamazaki N, Nozawa K, Fukuda H, Shibata T, Machida R, Hamaguchi T, Takashima A, Shoji H, Boku N, Takatsuka S, Takenouchi T, Nishina T, Yoshikawa S, Takahashi M, Hasegawa A, Kawazoe A, Masuishi T, Mizutani H, Kiyohara Y. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). Support Care Cancer. 2022 30(5):4497-4504. [PubMed]
9. Tsuji K, Matsuoka YJ, Kuchiba A, Suto A, Ochi E. Accuracy of exercise-based tests for estimating cardiorespiratory fitness and muscle strength in breast cancer survivors in Japan. Supportive Care in Cancer 2022 30(5):3857-3863. [PubMed]
10. Tsukamoto S, Kuchiba A, Moritani K, Shida D, Katayama H, Yorikane E,Kanemitsu Y. Laparoscopic surgery using 8 K ultra-high-definition technology: Outcomes of a phase II study. Asian J Endosc Surg. 2022 15(1):7-14. [PubMed]
11. Shimizu Y, Tsuji K, Ochi E, Okubo R, Kuchiba A, Shimazu T, Tatematsu N, Sakurai N, Iwata H, Matsuoka Y. Oncology care providers’ awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: A nationwide cross-sectional web-based survey. Supportive Care in Cancer 2022 30(4):3105-3118. [PubMed]
12. Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki  R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y. A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1. Cancer Science 2022 113(3):1018-1027. [PubMed]

2021年

原著論文

1. Yuwaki K, Kuchiba A, Otsuki A, Odawara M, Okuhara T, Ishikawa H, Inoue M, Tsugane S, Shimazu T. Effectiveness of a cancer risk prediction tool on lifestyle habits: a randomized controlled trial. Cancer Epidemiology, Biomarkers & Prevention. 2021 30(6):1063-71. [PubMed]
2. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Yasuhiro F. Clinical utility of circulating tumor DNA profiling in advanced rare cancers. Frontiers in Oncology 2021 11:732525. [PubMed]
3. Shimomura A, Tamura K, Tanaka K, Mizutani T, Sasaki K, Sekino Y, Sawaki M, Shien T, Shibata T, Iwata H. A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). Jpn J Clin Oncol. 2021 51(9):1471-1474. [PubMed]
4. Hara H, Uemura Y, Hayakawa K, Togano T, Asai Y, Matsunaga N, Terada M, Ohtsu H, Kitajima K, Shimizu Y, Sato L, Ishikane M, Kinoshita-Iwamoto N, Shibata T, Kondo M, Izumi K, Sugiura W, Ohmagari N. Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan, International Journal of Infectious Disesases. 2021 112時11分1-116. [PubMed]
5. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol. 2021 51(12):1757-1760. [PubMed]
6. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S, Toyoda A, Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clinical Infectious Diseases 2021 73(11):e3677-e3689. [PubMed]
7. Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Supportive Care in Cancer. 2021 29(5):2327-2334. [PubMed]
8. Tagawa T, Yamada M, Minagawa T, Sekiguchi M, Konda K, Tanaka H, Takamaru H, Sekiguchi M, Sakamoto T, Matsuda T, Kuchiba A, Yoshida H, Saito Y. Endoscopic characteristics influencing postpolypectomy bleeding in consecutive 1147 pedunculated colonic polyps: a multicenter retrospective study. Gastrointest Endosc. 2021 94(4):803-811.e6. [PubMed]
9. Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Gynecol Oncol. 2021 162(2):292-298. [PubMed]
10. Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 2021 142(2):323-338. [PubMed]
11. Ochi E, Tsuji K, Narisawa T, ShimizuY, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N. Matsuoka YJ. Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: a randomized controlled trial of the habit-B program. BMJ Supportive & Palliative Care. 2022 12(1):33-37. [PubMed]